|
... as a potential treatment for autoimmune diseases. The broad, parallel path of development in lupus, multiple sclerosis, and rheumatoid arthritis could result in the most rapid availability of this drug to patients around the globe. Converting to a ...
|
|
... inflammatory condition, which can lead to substantial loss of mobility due to pain and joint destruction. As a systemic disease, RA often affects extra-articular tissues throughout the body including the skin, blood vessels, heart, lungs, and ...
|
|
Oyinlola Abstract We have all at some time experienced the non-specific symptoms that arise from being ill following a systemic infection.
|
|
... be greater than 30%.2-3 Early detection and treatment is imperative. We report our experience with 4 patients with systemic sclerosis ILD, 2 with polymyositis ILD, 1 with Sjgren ILD, and 3 with rheumatoid arthritis (RA)-ILD,4 all of whom were ...
|
|
... provided benefit in several preclinical models of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus and that benefit was associated with an expansion of regulatory T cells. Ongoing pre-clinical ...
|